Per VLP Therapeutics:
Gaithersburg, MD — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21 million in a Series A-1 round from six investors, consisting of two new investors: Nobelpharma Co., Ltd.and MUFG Bank, Ltd., and four existing investors: Sojitz Corporation, MIYAKO Capital Co., Ltd., Mr. Robert G. Hisaoka and SK Impact Fund, LLC.
– Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants
– Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise and a 19.9-fold ACE2 inhibition increase after booster dose
Per the State of Maryland:
ANNAPOLIS, MD—Governor Larry Hogan today announced that, according to official CDC data, 90% of all Marylanders 18 and older have now received at least one dose of a COVID-19 vaccine. This is a major milestone for the state’s vaccination campaign.
MCPS has been doing targeted outreach to school families to help them make appointments. More appointments for the weekend clinics will be coming online later this morning. We expect supply to ramp up quickly but currently, supply is limited and demand is high.
— Montgomery County DHHS (@MoCoDHHS) November 5, 2021
Per Montgomery County:
We will offer COVID-19 vaccine doses to children ages 5 to 11 beginning Thursday, November 4. Appointments are required.
Novavax, a Gaithersburg-based biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced that the National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan (Badan POM), has granted emergency use authorization (EUA) for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. It will be manufactured by SII in India and marketed by SII in Indonesia under the brand name COVOVAX™.
“The first authorization of Novavax’ COVID-19 vaccine exemplifies our commitment to equitable global access and will fill a vital need for Indonesia, which despite being the fourth most populous nation on earth, continues to work to procure sufficient vaccine for its population,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “This also marks the first regulatory authorization worldwide of a protein-based COVID-19 vaccine based on Phase 3 clinical data demonstrating efficacy and a favorable safety profile. This is a landmark moment for Novavax and our partner, Serum Institute of India, and it is the first of many authorizations that Novavax expects in the coming weeks and months for our vaccine globally.”
Content verified October 29, 2021, courtesy of Montgomery County.
If you are eligible, you may choose any of the available COVID-19 vaccines as your booster. If you want a specific vaccine as your booster, check that your vaccination site has it available.
GAITHERSBURG, Md., Oct. 27, 2021/PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of its COVID-19 vaccine candidate. The company’s application for Conditional Marketing Authorization (CMA) marks the first submission for authorization of a protein-based COVID-19 vaccine in the United Kingdom.
“This submission brings Novavax significantly closer to delivering millions of doses of the first protein-based COVID-19 vaccine, built on a proven, well-understood vaccine platform that demonstrated high efficacy against multiple strains of the coronavirus,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We look forward to MHRA’s review and will be prepared to deliver vaccine doses following what we anticipate will be a positive decision. We thank the clinical trial participants and trial sites in the United Kingdom, as well as the U.K. Vaccines Taskforce, for their support and vital contributions to this program.”
Below you’ll see notes from Governor Larry Hogan’s 10/25 press conference, as tweeted by his Deputy Communications Director, Kata Hall:
• COVID-19 BOOSTERS. Maryland has already administered *280,000* booster shots.
These groups can currently get additional doses (booster shots and third doses):
We will update this page with guidance for Moderna and J&J vaccine recipients as soon as we get authorization from the CDC and State of Maryland.
These groups can currently get additional doses (booster shots and third doses):
Additional doses of J&J vaccine are not yet authorized.